Trial Profile

An Open-Label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma or NK/T-Cell Lymphoma After Failure of Conventional Chemotherapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jun 2011 Trial design presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Five patients have been enrolled to date.
14 Nov 2009 Actual initiation date (1 Nov 2009) added as reported by ClinicalTrials.gov.
14 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com